

[REDACTED]

From: [REDACTED]
Sent: Monday, 19 May 2014 9:17 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: FW: NBT Workshop Australia [SEC=UNCLASSIFIED]

Hi [REDACTED]

I received this email from [REDACTED] As you know [REDACTED] will be attending this Congress In Melbourne and [REDACTED] has just been advised that she will giving an oral presentation [Fifteen years of GM food safety assessment in Australia and New Zealand: perspectives and challenges] at this meeting.

We were unaware of this NBT workshop until this email arrived over the weekend. Do think that [REDACTED] could/should participate in this workshop?

Thanks

[REDACTED]

From: [REDACTED]
Sent: Saturday, 17 May 2014 4:50 AM
To: [REDACTED]
Subject: NBT Workshop Australia

[REDACTED]

[REDACTED] recommended I reach out to you regarding a "New Breeding Techniques" workshop that I am chairing at the 13th International Association of Plant Biotechnology (IAPB) Congress. The meeting will be taking place at the Melbourne Convention Centre, Melbourne, Australia August 10th-15th (<http://www.iapb2014.org/>).

The objectives of the NBT workshop will be to highlight the global NBT regulatory discussions currently taking place with special focus on Australia. FSANZ has been on the leading front of this topic and very proactive with the workshops and documents that it has produced so far. I would very much like to see if you or someone from FSANZ would be able to join the workshop to discuss the NBT workshops chaired by Peter Langridge in 2012, its outcomes and next steps FSANZ may be planning to take to address this global regulatory question?

Currently the planned agenda is as follows, but is open and flexible at this time:

1. **Short overview of "New Breeding Techniques" under global regulatory discussion** (ODM, site directed nucleases, RNA dependent DNA methylation, Agro-infiltration, reverse breeding, grafting of GMO, cisgenics/intragenics). Rudgers
2. **Examples of products being developed through NBTs** (invited Scion from NZ and they have accepted. Scion is a small company and can provide the small company perspective!
3. **Safety of products developed through NBTs compared to genomic variability in nature** – Bartholomaeus.
4. **Australia's regulatory/scientific opinion on regulatory oversight of NBT products and next steps forward** – FSANZ?
5. **Global status on regulatory decision making and the need for a harmonious global regulatory approach** – Rudgers
6. **Q&A**

As I mentioned, with the meeting in Australia I would REALLY like to highlight FSANZ work in this area to serve as a role model for other countries. If you feel you are unable to be a part of the workshop, could you recommend someone at FSANZ that may be able to participate?

I look forward to hearing from you and please let me know if I can help address any questions.

Best,

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]